// App-Quantinova.ai

: Long-Term Effects of Oral Eliglustat on Skeletal Manifestations of Gaucher Disease Type 1: Results from Four Completed Clinical Trials

Researchers

Presenter

  • Pramod K. Mistry

Principal Investigators

  • Joel Charrow

  • Timothy Cox

  • Elena Lukina

  • Theodore Marinakis

  • Meredith C. Foster

  • Sebastiaan J.M. Gaemers

  • Judith Peterschmitt

Medical Centers

  • Yale University, New Haven, CT

  • Northwestern University's Feinberg School of Medicine: Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL

  • The University of Cambridge, Addenbrookes Hospital, Cambridge, United Kingdom

  • National Research Center for Hematology, Moscow, Russia

  • General Hospital G. Gennimatas, Athens, Greece

  • Sanofi Genzyme, Cambridge, USA

Locations

  • United States

  • United Kingdom

  • Russia

  • Greece

Companies

  • N/A

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

  • Genetic Disorder

Disease

  • Gaucher disease

Biomarkers

  • N/A

Drug/Treatment

  • Eliglustat

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT00358150

  • NCT00891202

  • NCT00943111

  • NCT01074944

Sponsors

  • Sanofi Genzyme

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved